Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389494 | 1.00 | GCGR (0.34) | GCGRLGALS3LGALS1LGALS8SLC5A2 | |
| SCHEMBL4379884 | 0.88 | ESR1 (0.43) | GCGRLGALS3LGALS1SLC5A2ESR2 | |
| SCHEMBL4392394 | 0.88 | ESR1 (0.43) | GCGRLGALS3LGALS1SLC5A2ESR2 | |
| SCHEMBL4384949 | 0.87 | SLC5A2 (0.41) | SLC5A2ESR2TYRESR1 | |
| SCHEMBL4383993 | 0.87 | SLC5A2 (0.41) | SLC5A2ESR2TYRESR1 | |
| SCHEMBL4379299 | 0.87 | ESR1 (0.37) | GCGRSLC5A2ESR2ESR1 | |
| SCHEMBL4386494 | 0.87 | ESR1 (0.37) | GCGRSLC5A2ESR2ESR1 | |
| SCHEMBL6025149 | 0.87 | ESR1 (0.37) | GCGRSLC5A2ESR2ESR1 | |
| SCHEMBL4386407 | 0.84 | HDAC4 (0.37) | GCGRLGALS3LGALS1LGALS8SLC5A2 | |
| SCHEMBL4381472 | 0.84 | HDAC4 (0.37) | GCGRLGALS3LGALS1LGALS8SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | GCGR 263/4885LGALS3 4749/4885LGALS1 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.